« Return to News | R&D Trends

Research institute acquires Immune Tolerance Institute

Monday, June 13, 2011 09:45 AM

The David H. Murdock Research Institute (DHMRI) has acquired the Immune Tolerance Institute (ITI) as part of the North Carolina-based Institute’s mission to accelerate the discovery and development of breakthrough treatments for a range of immune-related diseases.

DHMRI provides integrated, state-of-the-art genomic, cellular, proteomic and bioinformatics technology platforms to both academic and industry partners undertaking both pre-clinical and clinical research.

By acquiring ITI, DHMRI will enhance its capabilities to accelerate the discovery of novel immunomodulatory therapies and of the corresponding biomarkers necessary for their effective translation into medical practice.

Biomarkers can help to better predict the course of disease progression and the likelihood of an individual's response to diet or therapeutic intervention, as well as serving as surrogate endpoints of mechanism, efficacy and safety.

"Advancing immune science will lead to new approaches to investigate the biological mechanisms of disease and functional properties of foods to better determine and predict the efficacy and safety of emerging products," said Mike Luther of the DHMRI. "The acquisition of ITI will allow us to extend the DHMRI's capabilities even further into the pre-clinical and clinical settings, ultimately improving the health of patients and consumers alike."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

May 20

IRB consolidation trend continues, as private equity firm Audax buys majority stake in Chesapeake

Quintiles, Merck Serono ink exclusive partnership

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.